BioNote, Inc. (KRX:377740)
South Korea · Delayed Price · Currency is KRW 5,820.00
-10.00 (-0.17%)
Last updated: Feb 20, 2026, 2:39 PM KST
BioNote Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | 117,649 | 55,261 | -20,497 | 307,798 | 676,601 | 528,229 |
Depreciation & Amortization | 8,845 | 8,186 | 8,206 | 6,451 | 4,106 | 1,887 |
Loss (Gain) From Sale of Assets | 55.25 | -20.25 | -265.2 | -13,412 | -361,225 | 11.45 |
Asset Writedown & Restructuring Costs | 4,835 | 4,835 | 8,409 | - | - | - |
Loss (Gain) From Sale of Investments | -5,222 | -9,386 | 5,000 | 5,150 | -15,047 | -544.38 |
Loss (Gain) on Equity Investments | -83,174 | 4,987 | 83,791 | -77,260 | - | -142,571 |
Stock-Based Compensation | 119.9 | 99.92 | - | 1,637 | 1,985 | 348.06 |
Provision & Write-off of Bad Debts | 62.32 | 62.32 | -2,845 | -3,596 | 6,827 | 470.16 |
Other Operating Activities | -13,878 | -12,749 | -82,440 | -4,089 | 34,137 | 172,526 |
Change in Accounts Receivable | -6,957 | -2,934 | 855.57 | 73,437 | 220,048 | -305,480 |
Change in Inventory | 8,374 | 10,632 | -436.63 | -33,543 | -9,826 | -48,141 |
Change in Accounts Payable | 134.11 | -982.63 | 221.23 | -4,573 | -22,140 | 27,513 |
Change in Other Net Operating Assets | 763.21 | -74.32 | -4,193 | -8,901 | 1,926 | 5,679 |
Operating Cash Flow | 31,606 | 57,917 | -4,194 | 249,100 | 537,392 | 239,926 |
Operating Cash Flow Growth | -22.77% | - | - | -53.65% | 123.98% | 2335.49% |
Capital Expenditures | -10,944 | -10,462 | -3,963 | -42,266 | -51,425 | -26,698 |
Sale of Property, Plant & Equipment | 7,443 | 727.18 | 94.36 | 49,399 | 174.43 | 78.08 |
Cash Acquisitions | - | - | - | - | -6,266 | - |
Sale (Purchase) of Intangibles | -102.8 | -19.66 | -579.33 | -217.44 | -118.58 | -23.59 |
Investment in Securities | -220,499 | -72,415 | -477,108 | -37,446 | -133,747 | -84,749 |
Other Investing Activities | - | 0 | 0 | - | - | - |
Investing Cash Flow | -224,103 | -82,170 | -481,555 | -30,530 | -191,383 | -111,393 |
Short-Term Debt Issued | - | - | 150,000 | - | - | - |
Long-Term Debt Issued | - | - | 10.5 | 50 | - | - |
Total Debt Issued | - | - | 150,011 | 50 | - | - |
Short-Term Debt Repaid | - | - | -150,000 | - | - | -12,000 |
Long-Term Debt Repaid | - | -1,144 | -836 | -415.58 | -216.76 | -79.83 |
Total Debt Repaid | -1,227 | -1,144 | -150,836 | -415.58 | -216.76 | -12,080 |
Net Debt Issued (Repaid) | -1,227 | -1,144 | -825.5 | -365.58 | -216.76 | -12,080 |
Issuance of Common Stock | - | - | 843.66 | 73,280 | - | - |
Repurchase of Common Stock | -3,935 | -3,108 | - | - | - | - |
Dividends Paid | -20,272 | -20,411 | -49,919 | -49,959 | -49,959 | - |
Other Financing Activities | - | - | - | -0 | -420 | 415 |
Financing Cash Flow | -25,435 | -24,663 | -49,901 | 22,955 | -50,596 | -11,665 |
Foreign Exchange Rate Adjustments | 4,996 | 8,862 | 1,978 | 20,930 | 118.56 | -364.69 |
Net Cash Flow | -212,936 | -40,054 | -533,672 | 262,455 | 295,532 | 116,504 |
Free Cash Flow | 20,661 | 47,454 | -8,156 | 206,834 | 485,966 | 213,228 |
Free Cash Flow Growth | -36.39% | - | - | -57.44% | 127.91% | 2458.84% |
Free Cash Flow Margin | 17.95% | 46.17% | -9.05% | 43.12% | 78.09% | 33.77% |
Free Cash Flow Per Share | 203.95 | 465.74 | -79.98 | 2193.65 | 5186.94 | 2279.15 |
Cash Interest Paid | 300.03 | 233.55 | 602.82 | 84.44 | 44.25 | 165.72 |
Cash Income Tax Paid | 15,871 | 5,003 | 40,454 | 157,006 | 171,252 | 993.03 |
Levered Free Cash Flow | -11,907 | 14,076 | -18,697 | 129,964 | 399,410 | 150,205 |
Unlevered Free Cash Flow | -11,720 | 14,222 | -18,321 | 130,017 | 399,438 | 150,313 |
Change in Working Capital | 2,313 | 6,640 | -3,553 | 26,420 | 190,009 | -320,430 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.